Abstract
The effects of β-cyclodextrin (β-CyD) and trehalose on glycation of human serum albumin (HSA) were studied. These additives reduced AGEs and nanofibril formation of HSA under in vitro glycation conditions and improved its helical structure. These were accomplished through direct interactions of them with HSA and alterations in solute-protein interactions.
Keywords: Diabetes, trehalose, β-cyclodextrin, glycation, HSA, glucose
Protein & Peptide Letters
Title: Inhibitory Effects of β-Cyclodextrin and Trehalose on Nanofibril and AGE Formation During Glycation of Human Serum Albumin
Volume: 16 Issue: 6
Author(s): Esmaeel Sharifi, Naghmeh Sattarahmady, Mehran Habibi-Rezaei, Mohammad Farhadi, Nader Sheibani, Faizan Ahmad and Ali Akbar Moosavi-Movahedi
Affiliation:
Keywords: Diabetes, trehalose, β-cyclodextrin, glycation, HSA, glucose
Abstract: The effects of β-cyclodextrin (β-CyD) and trehalose on glycation of human serum albumin (HSA) were studied. These additives reduced AGEs and nanofibril formation of HSA under in vitro glycation conditions and improved its helical structure. These were accomplished through direct interactions of them with HSA and alterations in solute-protein interactions.
Export Options
About this article
Cite this article as:
Sharifi Esmaeel, Sattarahmady Naghmeh, Habibi-Rezaei Mehran, Farhadi Mohammad, Sheibani Nader, Ahmad Faizan and Moosavi-Movahedi Akbar Ali, Inhibitory Effects of β-Cyclodextrin and Trehalose on Nanofibril and AGE Formation During Glycation of Human Serum Albumin, Protein & Peptide Letters 2009; 16(6) . https://dx.doi.org/10.2174/092986609788490212
DOI https://dx.doi.org/10.2174/092986609788490212 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Insulin Resistance, Obesity and the Metabolic Syndrome. Is there a Therapeutic Role for Endothelin-1 Antagonists?
Current Vascular Pharmacology Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Modulation of Mitochondrial Permeability Transition in Ischemia-Reperfusion Injury of the Heart. Advantages and Limitations
Current Medicinal Chemistry Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Protein Folding and Misfolding, Endoplasmic Reticulum Stress in Neurodegenerative Diseases: in Trace of Novel Drug Targets
Current Protein & Peptide Science Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Opportunistic Pathogens in Diabetic Foot Lesions
Current Diabetes Reviews Diabetic Cardiomyopathy and Oxidative Stress: Role of Antioxidants
Cardiovascular & Hematological Agents in Medicinal Chemistry From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Current Pharmaceutical Design The New Adipose Tissue and Adipocytokines
Current Diabetes Reviews Antioxidants in the Treatment of Diabetes
Current Diabetes Reviews Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets Effect of Antioxidants on Heavy Metals Induced Conformational Alteration of Cytochrome C and Myoglobin
Protein & Peptide Letters A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure
Current Vascular Pharmacology Conantokins Inhibitors of Ion Flow through the N-Methyl-D-Aspartate Receptor Channels
Current Drug Targets Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: “and Death Shall Have no Dominion”?
Current Vascular Pharmacology Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry